-transparent.png){kind=logo}
We formerly reported that the combination of dichloroacetate, omeprazole, and tamoxifen blocked cancer progression by reducing lactic acid production and inducing superoxide production. Recently, ivermectin, a well-known anti-parasite drug, was reported to share the same mechanisms with them and have anti-tumor activity. Here, we present three patients in whom the combination of dichloroacetate, omeprazole (plus tamoxifen), and ivermectin dramatically relieved the symptoms accompanying cancer and sarcoma progression.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Tatsuaki Ishiguro, and
Ryumei H Ishiguro, and
Miyu Ishiguro, and
Atsushi Toki, and
Hiroshi Terunuma
October 2016,
Oncotarget,
Tatsuaki Ishiguro, and
Ryumei H Ishiguro, and
Miyu Ishiguro, and
Atsushi Toki, and
Hiroshi Terunuma
September 2020,
Journal of Asian natural products research,
Tatsuaki Ishiguro, and
Ryumei H Ishiguro, and
Miyu Ishiguro, and
Atsushi Toki, and
Hiroshi Terunuma
January 2022,
International journal of analytical chemistry,
Tatsuaki Ishiguro, and
Ryumei H Ishiguro, and
Miyu Ishiguro, and
Atsushi Toki, and
Hiroshi Terunuma
July 2004,
The journal of gene medicine,
Tatsuaki Ishiguro, and
Ryumei H Ishiguro, and
Miyu Ishiguro, and
Atsushi Toki, and
Hiroshi Terunuma
December 2018,
Scientific reports,
Tatsuaki Ishiguro, and
Ryumei H Ishiguro, and
Miyu Ishiguro, and
Atsushi Toki, and
Hiroshi Terunuma
November 2021,
Cancers,
Tatsuaki Ishiguro, and
Ryumei H Ishiguro, and
Miyu Ishiguro, and
Atsushi Toki, and
Hiroshi Terunuma
January 2011,
Journal of biomedicine & biotechnology,
Tatsuaki Ishiguro, and
Ryumei H Ishiguro, and
Miyu Ishiguro, and
Atsushi Toki, and
Hiroshi Terunuma
February 2024,
Translational oncology,
Tatsuaki Ishiguro, and
Ryumei H Ishiguro, and
Miyu Ishiguro, and
Atsushi Toki, and
Hiroshi Terunuma
April 2022,
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
Tatsuaki Ishiguro, and
Ryumei H Ishiguro, and
Miyu Ishiguro, and
Atsushi Toki, and
Hiroshi Terunuma
January 2021,
Frontiers in oncology,
